Skip to content
Structural immunology

Publications

All publications: PUBMED LINK 

2026

  1. Pölläniemi, A, Miao, Y, Laitila, L, Piippo, H, Hammarén, M, Parikka, M et al.. Structural insights into multitargeting Pkn kinases. Microbiol Spectr. 2026;14 (8):e0004926. doi: 10.1128/spectrum.00049-26. PubMed PMID:42446239 PubMed Central PMC13435872.
  2. Miao, Y, Mykuliak, VV, Hubbard, SR, Silvennoinen, O, Hytönen, V, Haikarainen, T et al.. Janus kinase 2 activation loop as a regulator of catalysis and trans-activation. Int J Biol Macromol. 2026;374 :153276. doi: 10.1016/j.ijbiomac.2026.153276. PubMed PMID:42409141 .
  3. Lee, HK, Gorantla, SP, Haikarainen, T, Lee, SG, Caf, Y, von Bubnoff, N et al.. A rare JAK2 mutation associated with adult-onset Still’s disease and exacerbated vaccine-induced innate immune response. Rheumatology (Oxford). 2026;65 (5):. doi: 10.1093/rheumatology/keag207. PubMed PMID:41992501 .
  4. Lee, HK, Haikarainen, T, Caf, Y, Furth, PA, Knabl, L, Silvennoinen, O et al.. Heritability and Transcriptional Impact of JAK3, STAT5A and STAT6 Variants in a Tyrolean Family. Int J Mol Sci. 2026;27 (2):. doi: 10.3390/ijms27020913. PubMed PMID:41596571 PubMed Central PMC12842485.
  5. Haikarainen, T, Virtanen, AT, Cravatt, BF, Silvennoinen, O. Pharmacological targeting of the JAK-STAT pathway: new concepts and emerging indications. Nat Rev Drug Discov. 2026;25 (4):268-289. doi: 10.1038/s41573-025-01336-9. PubMed PMID:41486192 .

Search PubMed

2025

  1. Hennighausen, L, Haikarainen, T, Lee, SG, Caf, Y, Furth, PA, Silvennoinen, O et al.. Investigation of the transcriptional impact of rare germline JAK/STAT variants found in a Tyrolean alpine community. BMC Genomics. 2025;27 (1):8. doi: 10.1186/s12864-025-12307-0. PubMed PMID:41327031 PubMed Central PMC12771743.
  2. Soppela, S, González-Rodríguez, M, Stone, VM, Mustonen, I, Jouppila, NVV, Lampinen, V et al.. Coxsackie B1 virus-like particle vaccine modified to exclude a highly conserved immunoreactive region from the capsid induces potent neutralizing antibodies and protects against infection in mice. J Biomed Sci. 2025;32 (1):86. doi: 10.1186/s12929-025-01183-1. PubMed PMID:40922007 PubMed Central PMC12418688.
  3. Virtanen, A, Kettunen, V, Musta, K, Räkköläinen, V, Knapp, S, Haikarainen, T et al.. Molecular basis of JAK kinase regulation guiding therapeutic approaches: Evaluating the JAK3 pseudokinase domain as a drug target. Adv Biol Regul. 2025;95 :101072. doi: 10.1016/j.jbior.2024.101072. PubMed PMID:39755448 .

Search PubMed

2024

  1. Virtanen, A, Kettunen, V, Musta, K, Räkköläinen, V, Knapp, S, Haikarainen, T et al.. Molecular basis of JAK kinase regulation guiding therapeutic approaches: Evaluating the JAK3 pseudokinase domain as a drug target. Adv Biol Regul. 2025;95 :101072. doi: 10.1016/j.jbior.2024.101072. PubMed PMID:39755448 .
  2. Atomwise AIMS Program. Author Correction: AI is a viable alternative to high throughput screening: a 318-target study. Sci Rep. 2024;14 (1):21579. doi: 10.1038/s41598-024-70321-w. PubMed PMID:39284864 PubMed Central PMC11405665.
  3. Miao, Y, Virtanen, A, Zmajkovic, J, Hilpert, M, Skoda, RC, Silvennoinen, O et al.. Functional and Structural Characterization of Clinical-Stage Janus Kinase 2 Inhibitors Identifies Determinants for Drug Selectivity. J Med Chem. 2024;67 (12):10012-10024. doi: 10.1021/acs.jmedchem.4c00197. PubMed PMID:38843875 PubMed Central PMC11215726.
  4. Atomwise AIMS Program. AI is a viable alternative to high throughput screening: a 318-target study. Sci Rep. 2024;14 (1):7526. doi: 10.1038/s41598-024-54655-z. PubMed PMID:38565852 PubMed Central PMC10987645.
  5. Abraham, BG, Haikarainen, T, Vuorio, J, Girych, M, Virtanen, AT, Kurttila, A et al.. Molecular basis of JAK2 activation in erythropoietin receptor and pathogenic JAK2 signaling. Sci Adv. 2024;10 (10):eadl2097. doi: 10.1126/sciadv.adl2097. PubMed PMID:38457493 PubMed Central PMC10923518.

Search PubMed

2023

  1. Saarikettu, J, Lehmusvaara, S, Pesu, M, Junttila, I, Partanen, J, Sipilä, P et al.. The RNA-binding protein Snd1/Tudor-SN regulates hypoxia-responsive gene expression. FASEB Bioadv. 2023;5 (5):183-198. doi: 10.1096/fba.2022-00115. PubMed PMID:37151849 PubMed Central PMC10158624.
  2. Pölläniemi, A, Virtanen, A, Silvennoinen, O, Haikarainen, T. Development of an enzyme-coupled activity assay for Janus kinase 2 inhibitor screening. SLAS Discov. 2023;28 (4):180-187. doi: 10.1016/j.slasd.2023.05.001. PubMed PMID:37149038 .
  3. Virtanen, A, Palmroth, M, Liukkonen, S, Kurttila, A, Haikarainen, T, Isomäki, P et al.. Differences in JAK Isoform Selectivity Among Different Types of JAK Inhibitors Evaluated for Rheumatic Diseases Through In Vitro Profiling. Arthritis Rheumatol. 2023;75 (11):2054-2061. doi: 10.1002/art.42547. PubMed PMID:37134144 .
  4. Virtanen, AT, Haikarainen, T, Sampathkumar, P, Palmroth, M, Liukkonen, S, Liu, J et al.. Identification of Novel Small Molecule Ligands for JAK2 Pseudokinase Domain. Pharmaceuticals (Basel). 2023;16 (1):. doi: 10.3390/ph16010075. PubMed PMID:36678572 PubMed Central PMC9865020.

Search PubMed